Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: Patients with schizophrenia have a high prevalence of metabolic disorders and cardiovascular mortality. It is possible that a vulnerability to metabolic abnormalities is associated with risk for psychosis, symptoms and functionality. In this study, we evaluate demographic information, cardiometabolic indices, symptoms and functioning in an antipsychotic free cohort at Clinical High Risk (CHR) for psychosis from the NAPLS Omega 3 Fatty Acid Clinical Trial. Method: Subjects received physical exams and metabolic monitoring prior to randomization into the Omega 3 versus Placebo trial. Anthropometrical measures, vital signs, glucose, and lipids were assessed along with symptoms, functioning, dietary Omega 3 fatty acids, erythrocyte polyunsaturated fatty acid content and a measure of lipid peroxidation (TBARS, Thiobarbituric acid-reactive substances). Results: The sample included 113 CHR subjects (42.1% female; 17.5% Latino) ages 12–29. The mean BMI was 24.3 with a trend toward higher BMI and a higher incidence of metabolic syndrome in Latino subjects; 36% of the sample was obese/overweight; 37.6% met criteria for prehypertension/hypertension; 4.2% met criteria for prediabetes/diabetes; 9.6% showed evidence of insulin resistance and 44.7% had dyslipidemia. The TBARS was elevated at 9.8 μM±6.1 (normal 1.86–3.94 μM). Metabolic parameters and a diet low in Omega 3 rich foods were signicantly associated with prodromal symptoms and poor functioning. Conclusions: CHR subjects show a high percentage of metabolic abnormalities prior to exposure to antipsychotic medication. These ndings reinforce that early detection of metabolic disturbances and food insecurity is crucial since these factors are modiable with the potential for signicant gains in terms of quality of life, physical and mental health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111
DE HERT, M., COHEN, D., BOBES, J., CETKOVICH‐BAKMAS, M., LEUCHT, S., NDETEI, D. M., NEWCOMER, J. W., UWAKWE, R., ASAI, I., MÖLLER, H., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00036.x · Cited by 870 · cited 1×
“…the mortality and morbidity among individuals with schizophrenia are due to natural causes, such as cancer, respiratory diseases and cardiovascular disease (CVD) (Colton and Manderscheid, 2006; De Hert et al., 2011), with CVD mortality ranging from 40–50% in most studies (De Hert et al., 2011).”
BackgroundExcess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384
Review: Mortality in schizophrenia: a measurable clinical endpoint
Bushe, C. J., Taylor, M., & Haukka, J. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382468 · Cited by 185 · cited 2×
“5- to 3-fold increase in mortality rate in schizophrenia (Brown, 1997; Bushe et al., 2010; McGrath et al., 2008) with a 15–20 year shortened life expectancy compared to that of the general population (Bushe et al.”
BackgroundBrain White Matter Expansion in Human Obesity and the Recovering Effect of Dieting
Haltia, L. T., Viljanen, A., Parkkola, R., Kemppainen, N., Rinne, J. O., Nuutila, P., & Kaasinen, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2495 · Cited by 139 · cited 1×
“…in otherwise healthy individuals show that obesity/overweight-related brain structural abnormalities might be reversible with weight loss and dietetic interventions, in particular when adolescents and young adults are targeted (Gomez-Pinilla, 2011; Haltia et al., 2007; Mueller et al., 2015).”
Background
Cited by
Potential Roles of Redox Dysregulation in the Development of Schizophrenia
Perkins, D. O., Jeffries, C. D., & Do, K. Q. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.03.016 · Cited by 103
Self-citationCullen, A. E., Addington, J., Bearden, C. E., Stone, W. S., Seidman, L. J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., et al. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104649 · Cited by 34
Self-citationOmega‐3 fatty acid in ultra‐high‐risk psychosis: A systematic review based on functional outcome
Susai, S. R., Sabherwal, S., Mongan, D., Föcking, M., & Cotter, D. R. (2022) · Early Intervention in Psychiatry · doi:10.1111/eip.13133 · Cited by 19
“TABLE 4 Risk of bias assessment (ROB) ROB 2 assessment for individual randomized trials VHR NEURAPRO Domain 1 Risk of bias arising from the randomization process Low Low Type of the study Name/place of the study Availability of data References Assessment of dietary omega-3 PUFA Erythrocyte omega-3 measurement Function…”
BackgroundMethodInfluential
Metadata
- Authors
- Cadenhead, K. S., Minichino, A., Kelsven, S., Addington, J., Bearden, C., Cannon, T. D., Cornblatt, B. A., Mathalon, D., McGlashan, T. H., Perkins, D. O., Seidman, L. J., Tsuang, M., Walker, E. F., Woods, S. W., & Yao, J.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 204
- Pages
- 96-103
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2892783028
- Cited by
- 50
- References
- 8
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.